hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06356298, orgStudyIdInfo id: MCHH_004, briefTitle: Flexible Reinforced Laryngeal Mask Airway Versus Endotracheal Tube for Childhood Adenotonsillectomy, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-08-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Maternal and Child Health Hospital of Hubei Province, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare the airway management effects of flexible reinforced laryngeal mask and endotracheal tube in childhood adenotonsillectomy.Participants will be randomly allocated to two groups: endotracheal tube group (ETT) and flexible reinforced laryngeal mask group (FLMA). For those in ETT group: they will be intubated after induction of anesthesia .For those in FLMA group: they will be put in flexible reinforced laryngeal mask after induction of anesthesia .The investigators will compare FLMA with ETT to see if flexible reinforced laryngeal mask can be used safely and effectively in childhood adenotonsillectomy，and if there will be less severe adverse events in FLMA., conditionsModule conditions: Anesthesia Intubation Complication, conditions: Airway, conditions: Adenotonsillectomy, conditions: Children, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ACTUAL, armsInterventionsModule interventions name: Airway Management: Flexible Reinforced Laryngeal Mask Airway, interventions name: Airway Management: Endotracheal Tube, outcomesModule primaryOutcomes measure: Peak airway pressure, primaryOutcomes measure: Petco2, primaryOutcomes measure: Ventilation leakage or not, secondaryOutcomes measure: Mean arterial pressure (MAP), secondaryOutcomes measure: Heart rate (HR), secondaryOutcomes measure: Recovery time, secondaryOutcomes measure: Extubation time, secondaryOutcomes measure: Dosage of anesthetic, secondaryOutcomes measure: Success of FLMA or ETT, secondaryOutcomes measure: Surgeon satisfaction, secondaryOutcomes measure: Adverse events, eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule locations facility: Maternal and Child Health Hospital of Hubei Province, city: Wuhan, state: Hubei, zip: 430000, country: China, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06356272, orgStudyIdInfo id: 19-006036, secondaryIdInfos id: NCI-2024-00965, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 19-006036, type: OTHER, domain: Mayo Clinic Institutional Review Board, briefTitle: Oropharynx (OPX) Biomarker Trial, statusModule overallStatus: RECRUITING, startDateStruct date: 2019-11-15, primaryCompletionDateStruct date: 2024-12-15, completionDateStruct date: 2025-12-15, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent., conditionsModule conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, conditions: Metastatic Oropharyngeal Squamous Cell Carcinoma, conditions: Oropharyngeal Squamous Cell Carcinoma, conditions: Recurrent Oropharyngeal Squamous Cell Carcinoma, conditions: Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, conditions: Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: Non-Interventional Study, outcomesModule primaryOutcomes measure: Change in biomarkers, primaryOutcomes measure: Oncologic outcomes associated with biomarkers, primaryOutcomes measure: Genetic alterations, primaryOutcomes measure: Immunologic biomarkers for predicting progression free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Diane Vogen, role: CONTACT, phone: 507-266-1247, email: Vogen.Diane2@mayo.edu, contacts name: Kathryn M. Van Abel, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06356259, orgStudyIdInfo id: IMMUNRX-01, secondaryIdInfos id: 2023-503917-31, type: EUDRACT_NUMBER, briefTitle: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-07, primaryCompletionDateStruct date: 2025-01-22, completionDateStruct date: 2025-01-22, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: ImmunoRx Pharma Inc., class: INDUSTRY, descriptionModule briefSummary: The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics with intravenous(IV) administration of IRX-010 in Healthy Participants., conditionsModule conditions: Healthy Participants, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 81, type: ESTIMATED, armsInterventionsModule interventions name: IRX-010, interventions name: Placebo, outcomesModule primaryOutcomes measure: Number of participants with Serious Adverse Events, primaryOutcomes measure: Number of participants with Treatment-Emergent Adverse Events, secondaryOutcomes measure: Pharmacokinetics(PK): Area under Curve(AUC), secondaryOutcomes measure: Pharmacokinetics(PK): Maximum Concentration (Cmax), secondaryOutcomes measure: Pharmacokinetics(PK): Half-Life (t½), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ICON, status: RECRUITING, city: Groningen, zip: 9728, country: Netherlands, contacts name: Renger Tiessen, role: CONTACT, contacts name: Renger Tiessen, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 53.21917, lon: 6.56667, hasResults: False
protocolSection identificationModule nctId: NCT06356233, orgStudyIdInfo id: FIMBEX, briefTitle: Phenotyping and Identification of Biological Markers in STXBP1 Encephalopathy, acronym: FIMBEX, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-10-01, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Fundación Iniciativa para las Neurociencias (FINCE), class: OTHER, descriptionModule briefSummary: This is a prospective observational study to evaluate the phenotype of 10 patients under 10 years of age with developmental epileptic encephalopathy due to mutation of the STXBP1 gene. The study will consist of a clinical and neurodevelopmental evaluation, magnetic resonance imaging, prolonged electroencephalogram, cardiological study, and analysis of biomarkers in cerebrospinal fluid. These patients will be followed up for 3 years. The aim of the study is, knowing the baseline phenotype, to analyse the response to commonly used drugs and to anticipate the response to different drugs available on the market in this group of patients based on clinical and biomarker assessment (EEG, MRI and study of specific proteins and neurotransmitters in plasma, urine and CSF)., conditionsModule conditions: STXBP1 Encephalopathy With Epilepsy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: No intervention will be performed, outcomesModule primaryOutcomes measure: CSF biomarkers, primaryOutcomes measure: EEG markers, primaryOutcomes measure: MRI markers, secondaryOutcomes measure: Clinical phenotype, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule locations facility: Hospital Ruber Internacional, city: Madrid, zip: 28034, country: Spain, contacts name: Alvaro Beltran Corbellini, MD, role: CONTACT, phone: +34913875250, email: info@neurologiaclinica.es, contacts name: Antonio Gil-Nagel, MD, PhD, role: CONTACT, contacts name: Antonio Gil-Nagel, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False
protocolSection identificationModule nctId: NCT06356220, orgStudyIdInfo id: IRB-P00046867, briefTitle: GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health), acronym: GF-NOURISH, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2026-01, completionDateStruct date: 2026-07, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Boston Children's Hospital, class: OTHER, descriptionModule briefSummary: We propose the Gluten Free Nutrition Optimization through Ultra-processed food Reduction and Improved Strategies for Health (GF-NOURISH) study to demonstrate the feasibility and success of a nutritional education program focused on naturally occurring gluten-free foods and minimizing ultra-processed gluten-free foods. We hypothesize that nutritional educational (GF-NOURISH) intervention will have multiple health benefits, conditionsModule conditions: Celiac Disease in Children, conditions: Nutrition Disorder, Child, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 1. Study Design: Prospective randomized controlled trial.2. Study population: Children (N=120) with newly diagnosed CeD3. Intervention: Gluten-Free Food Guide, a nutritional education program focused on minimizing ultra-processed foods in gluten-free die(GFFG), OR a conventional GFD nutritional education class. The nutrition educational program will be based on validated GFD education program. We will use a randomized control trial to assess improvement of overall diet quality, changes in body composition, and minimize toxic and nutrient metal exposures associated with processed gluten-free foods., primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Gluten-Free Diet Education, outcomesModule primaryOutcomes measure: To compare the effect of GFFG versus conventional GFD class on body composition, specifically fat free mass, secondaryOutcomes measure: To compare the effect of GFFG vs conventional GFD class on diet quality, secondaryOutcomes measure: To compare the effect of GFFG versus conventional GFD on arsenic exposure, eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Boston Children's Hospital, city: Boston, state: Massachusetts, zip: 02115, country: United States, contacts name: Lauren Robertson, role: CONTACT, contacts name: Nan Du, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06356207, orgStudyIdInfo id: 113-2023, briefTitle: Syncope-Asystole Latency Time in Tilt Table Test: The SALT-TILT Study, acronym: SALT-TILT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Azienda Ospedaliera di Bolzano, class: OTHER, descriptionModule briefSummary: Syncope is a common presenting condition. Pacemaker implantation can significantly reduce syncope recurrences in reflex syncope. However, despite careful selection, a substantial proportion of patients treated with pacemakers suffer recurrences of syncope. It is thought that a pronounced vasodepressor component may hinder the efficacy of pacing in patients, preventing adequate cerebral perfusion during the reflex, thus relativizing the anti-bradycardia function of the pacemaker to prevent syncope. It is hypothesised that the time elapsed from the actual loss of consciousness to the asystole recorded on the ECG during Tilt Table Test may be predictive in terms of response to pacemaker therapy, so this parameter becomes the subject of the present study., conditionsModule conditions: Syncope, conditions: Pacemaker, conditions: Asystole, conditions: Neurally Mediated Syncope, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Tilt Table Test, outcomesModule primaryOutcomes measure: SALT (Syncope-Asystole Latency Time), secondaryOutcomes measure: Recurrence of syncope, secondaryOutcomes measure: Recurrence of syncope, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Azienda Sanitaria di Bolzano, status: RECRUITING, city: Bolzano, zip: 39100, country: Italy, contacts name: Marco Tomaino, Dr., role: CONTACT, geoPoint lat: 46.49067, lon: 11.33982, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-12-06, uploadDate: 2024-04-04T15:15, filename: Prot_SAP_000.pdf, size: 334779, hasResults: False
protocolSection identificationModule nctId: NCT06356194, orgStudyIdInfo id: AT-01B-006, briefTitle: Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-05-30, completionDateStruct date: 2024-05-30, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Atea Pharmaceuticals, Inc., class: INDUSTRY, descriptionModule briefSummary: Drug-drug interaction study of Biktarvy and Bemnifosbuvir/Ruzasvir, conditionsModule conditions: Healthy Volunteer Study, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK, interventions name: Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered., outcomesModule primaryOutcomes measure: PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine) on the pharmacokinetics (PK) of Bemnifosbuvir (BEM) and Ruzasvir (RZR)., primaryOutcomes measure: To determine the effect of Bemnifosbuvir (BEM)/Ruzasvir (RZR) combination on the PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Atea Study Site, city: Québec, state: Montreal, country: Canada, contacts name: Atea Study Site, role: CONTACT, phone: 888-481-1607, email: ateaclinicaltrials@ateapharma.com, geoPoint lat: 46.81228, lon: -71.21454, hasResults: False
protocolSection identificationModule nctId: NCT06356181, orgStudyIdInfo id: Pro00135143, briefTitle: Training Adaptations With and Without Ventilatory Training Device, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: University of South Carolina, class: OTHER, collaborators name: MAXIMUS, descriptionModule briefSummary: This project aims to assess the effectiveness of using a Respiratory Muscle Training (RMT) device during high-intensity functional training (HIFT) to improve fitness and ventilatory parameters. Primary outcome measures include aerobic, anaerobic, and HIFT measures. Secondary measures include sleep, affect, and mood state questionnaires. Participants will be randomized into one of two groups: with the RMT device and without the RMT device., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Respiratory Maximus Training Device, interventions name: No Respiratory Training Device, outcomesModule primaryOutcomes measure: Changes in spirometry, primaryOutcomes measure: Changes in aerobic capacity, primaryOutcomes measure: Changes in peak power, primaryOutcomes measure: Changes in ventilatory threshold, primaryOutcomes measure: Changes in countermovement jump, primaryOutcomes measure: Changes in anaerobic capacity, primaryOutcomes measure: Changes in high-intensity functional training test, primaryOutcomes measure: Changes in heart rate at ventilatory threshold, secondaryOutcomes measure: Changes in body composition, secondaryOutcomes measure: Changes in sleep quality, secondaryOutcomes measure: Changes in total mood disturbances, secondaryOutcomes measure: Changes in positive mood and emotion, secondaryOutcomes measure: Change in blood lactate responses, secondaryOutcomes measure: Changes in negative mood and emotion, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of South Carolina Sport Science Lab, status: RECRUITING, city: Columbia, state: South Carolina, zip: 29208, country: United States, contacts name: Shawn M. Arent, PhD, role: CONTACT, phone: 803-576-8394, email: sarent@mailbox.sc.edu, contacts name: Sten O Stray-Gundersen, PhD, role: CONTACT, email: sten@mailbox.sc.edu, geoPoint lat: 34.00071, lon: -81.03481, hasResults: False
protocolSection identificationModule nctId: NCT06356168, orgStudyIdInfo id: SVR/IVR, briefTitle: Virtual Reality in End Stage Kidney Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-01-31, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: University of Pennsylvania, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial to compare the social virtual reality and individual virtual reality in patients with end stage kidney disease who are hemodialysis. The main aim is to determine if there are differences in symptoms between the groups. Participants will use virtual reality glasses for 30-45 minutes during dialysis sessions for 4 weeks., conditionsModule conditions: End Stage Kidney Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Social Virtual Reality, interventions name: Individual Virtual Reality, outcomesModule primaryOutcomes measure: De Jong Gierveld Scale, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06356142, orgStudyIdInfo id: UMMC-IRB-2023-317, briefTitle: The Effects of Palmar Cooling on Repeated Sprinting Ability, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-04, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: University of Mississippi Medical Center, class: OTHER, descriptionModule briefSummary: Repeated sprinting ability is key for athletic performance in a variety of sport settings. Significant degradations in work output (i.e. fatigue) have been shown to develop after just one sprinting bout1. This pilot study aims to investigate the effects that noninvasive transient temperature manipulation has on an individual's ability to perform repeated sprints. The investigators aim to enroll 90 healthy individuals, 18-30 years of age. Participants will be randomized into two groups (Group A, and B). All groups will perform a ten-minute warm-up followed by two minutes of rest. Following the warm-up and rest period, all groups will participate in a series of five sprints, 60 meters in total length with two 180 degree changes in direction. Between sprints, participants will have 10 seconds rest. After the first series of five sprints participants will be given a 2-minute rest interval. Then participants will perform another series of five sprints followed by another 2-minute rest interval. During each rest interval, Group A will utilize a palmar cooling device. Group B will utilize a placebo version of the palmar cooling device. All sprints will be timed. Heart rate recovery will be measured during all rest breaks, and a rating of perceived exertion will be measured at the beginning and end of each resting interval. Delayed onset muscle soreness will be assessed 48 hours post sprinting, utilizing a visual analog scale., conditionsModule conditions: Exercise Induced Fatigue, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Palmar Cooling, interventions name: Placebo Palmar Cooling, outcomesModule primaryOutcomes measure: Participants Sprinting times, secondaryOutcomes measure: Participants Heart Rate Recovery, secondaryOutcomes measure: Participants Rating of Perceived exertion, secondaryOutcomes measure: Participants Reported Delayed Onset Muscle Soreness, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of Mississippi Medical Center, city: Jackson, state: Mississippi, zip: 39216, country: United States, contacts name: Jacob Daniels, DPT, EdD, role: CONTACT, phone: 601-815-4038, email: jbdaniels@umc.edu, geoPoint lat: 32.29876, lon: -90.18481, hasResults: False